These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 2552029)
1. In vitro activity of YTR 830. Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029 [TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420 [TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Fass RJ; Prior RB Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904 [TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203 [TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases. Gatermann S; Marre R Infection; 1991; 19(2):106-9. PubMed ID: 1646771 [TBL] [Abstract][Full Text] [Related]
7. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads. Jacobs MR; Aronoff SC; Johenning S; Yamabe S J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984 [TBL] [Abstract][Full Text] [Related]
8. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Nomura S; Hanaki H; Nagayama A J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745 [TBL] [Abstract][Full Text] [Related]
9. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017 [TBL] [Abstract][Full Text] [Related]
10. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241 [TBL] [Abstract][Full Text] [Related]
11. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Jones RN; Pfaller MA; Fuchs PC; Aldridge K; Allen SD; Gerlach EH Diagn Microbiol Infect Dis; 1989; 12(6):489-94. PubMed ID: 2560421 [TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Sader HS; Tosin I; Sejas L; Miranda E Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842 [TBL] [Abstract][Full Text] [Related]
13. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Aronoff SC; Jacobs MR; Johenning S; Yamabe S Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria. Kuck NA; Petersen PJ; Weiss WJ; Testa RT J Chemother; 1989 Jun; 1(3):155-61. PubMed ID: 2552030 [TBL] [Abstract][Full Text] [Related]
15. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Knapp CC; Sierra-Madero J; Washington JA Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423 [TBL] [Abstract][Full Text] [Related]
16. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors. Moosdeen F; Keeble J; Williams JD Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004 [TBL] [Abstract][Full Text] [Related]
17. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae. Simonet M; Moittie D; Philippon A; Descamps P; Veron M J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748 [No Abstract] [Full Text] [Related]
18. An evaluation of the in vitro activity of piperacillin/tazobactam. Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825 [TBL] [Abstract][Full Text] [Related]
19. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria. Nord CE J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398 [No Abstract] [Full Text] [Related]
20. Beta-lactamase inhibitors and Acinetobacter spp. Eng RH; Smith SM; Cherubin CE J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200 [No Abstract] [Full Text] [Related] [Next] [New Search]